Pipeline Database
UB354
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB354
IndicationsVaricella zoster virus infection
ClinicalCN - II
TherapeuticsInfectious Diseases
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- World's first lyophilized mRNA Herpes Zoster (Shingles) vaccine to enter clinical trials, overcoming the ultra-cold chain logistics barrier inherent to traditional mRNA vaccines.
- Currently in Phase I Clinical Trial (CDE approved), built on a proprietary full-domain mRNA technology platform with comprehensive IP coverage, minimizing patent infringement risks.
- Positioned as a potential "Best-in-Class" product, targeting the global aging market with superior stability and accessibility compared to GSK's Shingrix and other frozen liquid mRNA competitors.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →